Methylphenidate Hydrochloride Tablet, Extended Release
Product Images NDC 0406-0127

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Methylphenidate Hydrochloride (NDC 0406-0127). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Specgx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Methylphenidate Hydrochloride Er Tablets 1)

This appears to be a chemical compound description. The compound is labeled as Ox OCHs and has a molecular weight of 269.77 g/mol. Further information about this compound is not available.*

FDA Label Image

Figure 1 (Methylphenidate Hydrochloride Er Tablets 2)

This is a table showing the mean plasma methylphenidate concentration in ng/mL for two different dosage regimens of methylphenidate HCl extended-release tablets, one being 18mg once daily and the other being 5mg three times daily.*

FDA Label Image

Figure 2 (Methylphenidate Hydrochloride Er Tablets 3)

FDA Label Image

Figure 3 (Methylphenidate Hydrochloride Er Tablets 4)

This is a table providing information on the effects of Methylphenidate Hydrochloride Extended-Release Tablets and Placebo on the Combined Attention Subscale. The table shows the results for two groups of participants at various hours post initial dosage. The values are presented in mean and mean plus standard error of the mean.*

FDA Label Image

Principal Display Panel (27 mg Bottle)

NDC 0406-0127-01 is a medication in the form of 100 tablets, each containing Methylphenidate Hydrochloride USP 27 mg in an extended-release formulation. The usual dosage is once daily, and it should be stored at controlled room temperature, protected from humidity. Pharmacists should dispense the medication guide and provide individual patient instructions. The medication is distributed by Mallinckrodt in the USA.*

FDA Label Image

Principal Display Panel (36 mg Bottle)

This is a medication description for NDC 0406-0136-01 tablets containing Methylphenidate hydrochloride USP in an extended-release formulation. The usual dosage is once daily, and the tablets should be protected from humidity and dispensed in tight, light-resistant containers. The medication guide should be provided to each patient. The address of the manufacturer is also included.*

FDA Label Image

Principal Display Panel (54 mg Bottle)

NDC 0406-0154-01 is a medication that comes in a package of 100 tablets, each containing Methylphenidate Hydrochloride USP 54mg. It is an extended-release tablet used for treating hyperactivity/Attention Deficit Disorder (ADHD). The tablets should be stored between 20 to 25°C (68° to 77°F) or 30°C (59° to 86°F). The label warns that the medication should be kept protected from moisture in a tightly sealed container. The medication guide should be dispensed with the drug, and this drug should be dispensed only with a child-resistant cap to prevent accidental ingestion. The manufacturer of the medication is Mallinckrodt Pharmaceuticals.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.